Replimune Group, Inc. — Investor Relations & Filings
Filings indexed
586
across all filing types
Latest filing
2026-02-20
Director's Dealing
Country
US
United States of America
Listing
US
REPL
Replimune Group, Inc. is a clinical-stage biotechnology company that develops oncolytic immunotherapies to treat cancer. The company's approach utilizes a proprietary platform to engineer viruses that are intended to selectively replicate within and destroy tumors while also activating a powerful, systemic, and durable anti-tumor immune response. Replimune's product candidates are being developed to treat a broad range of solid tumors, both as monotherapies and in combination with other cancer treatments. The company's mission is to revolutionize cancer treatment by inducing a comprehensive, tumor-specific immune activation.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 4 - REPLIMUNE GROUP, INC. (0001737953) (Filer) | 2026-02-20 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| 10-Q Filing | 2026-02-03 | English | |
| 8-K Filing | 2026-02-03 | English | |
| FORM 8-K | 2026-01-12 | English | |
| OWNERSHIP DOCUMENT | 2025-12-19 | English |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
5 filings
| |||||
| 32897518 | 4 - REPLIMUNE GROUP, INC. (0001737953) (Filer) | 2026-02-20 | English | ||
| 31534227 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31534414 | 10-Q Filing | 2026-02-03 | English | ||
| 31534363 | 8-K Filing | 2026-02-03 | English | ||
| 13106220 | FORM 8-K | 2026-01-12 | English | ||
|
2025
10 filings
| |||||
| 13106221 | OWNERSHIP DOCUMENT | 2025-12-19 | English | ||
| 13106224 | OWNERSHIP DOCUMENT | 2025-12-19 | English | ||
| 13106223 | OWNERSHIP DOCUMENT | 2025-12-19 | English | ||
| 13106225 | OWNERSHIP DOCUMENT | 2025-12-19 | English | ||
| 13106222 | OWNERSHIP DOCUMENT | 2025-12-19 | English | ||
| 13106227 | OWNERSHIP DOCUMENT | 2025-12-11 | English | ||
| 13106228 | Regulatory Filings 2025 | 2025-12-09 | English | ||
| 13106229 | OWNERSHIP DOCUMENT | 2025-12-04 | English | ||
| 13106231 | Regulatory Filings 2025 | 2025-12-02 | English | ||
| 13106230 | OWNERSHIP DOCUMENT | 2025-11-19 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Beijing Sun-Novo Pharmaceutical Research Co.,Ltd.
Integrated CRO providing full-spectrum R&D from drug discov…
|
688621 | CN | Professional, scientific and te… |
|
BenevolentAI
Applies artificial intelligence to accelerate drug discover…
|
BAI | LU | Professional, scientific and te… |
|
Berry Genomics Co.,Ltd
Provides clinical genomics and genetic testing for prenatal…
|
000710 | CN | Professional, scientific and te… |
|
BetterLife Pharma
Developing non-hallucinogenic neuroplastogens for severe ne…
|
BETR | CA | Professional, scientific and te… |
|
BGI Genomics Co., Ltd.
Provides integrated solutions for precision medicine via ge…
|
300676 | CN | Professional, scientific and te… |
|
bioAffinity Technologies, Inc.
Develops noninvasive diagnostics and targeted therapeutics …
|
BIAF | US | Professional, scientific and te… |
|
BioArctic
Biopharmaceutical firm developing antibody therapies for ne…
|
BIOA | SE | Professional, scientific and te… |
|
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Develops antibody therapeutics using proprietary RenMice ge…
|
688796 | CN | Professional, scientific and te… |
|
BIO-GENE TECHNOLOGY LTD
Develops novel insecticides from natural chemistry to comba…
|
BGT | AU | Professional, scientific and te… |
|
BioInfra Co.,Ltd.
Develops multi-biomarker blood tests for early cancer scree…
|
199730 | KR | Professional, scientific and te… |
Replimune Group, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33193/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33193 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33193 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33193 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33193}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Replimune Group, Inc. (id: 33193)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.